



**Larifan & Orioled HUB**  
**Innovative Biopharmaceutical and UK Registration**  
**Joint Project with Advance Medicinal Consulting Ltd**

## Introduction

# 1. Introduction

- Combining the expertise and resources of Orioled HUB (RA and business partner) and Larifan (owner and manufacturer of the innovative dsRNA biopreparation).
- Establishment of the British company Advance Medicinal Consulting Ltd for the registration and promotion of Larifan injections in the UK market.
- Goal: MHRA registration and strengthening presence with the expansion of the cosmetic product line.

## 2. Market Problem

### Increased Viral Diseases

Increase in viral diseases and immune disorders in Europe and the UK.

### Need for Safe Drugs

Need for safe and effective biopreparations with a natural mechanism of action.

### Limitations of Conventional Treatments

Limitations of classical antiviral agents and immunomodulators.

## 3. Solution — Larifan

- Biopreparation based on dsRNA — an interferon inducer, stimulating natural immunity.
- Treatment and prevention of recurrent viral infections , immune support, and immuno-oncological activity.
- Various forms of release: injectable preparation and cosmetic products.



## 4. Scientific Basis and Evidence

### 50+ Years of Research

Over 50 years of scientific research, clinical and preclinical data with confirmed efficacy and safety.

### Active Application


The drug has been actively used in EU countries since 1995, Asia (Vietnam since 2020), Georgia, Azerbaijan, Kazakhstan, etc.

### 3 Actions Confirmed Efficacy

Confirmed antiviral, immunomodulatory, and antitumor effects.

# 5. Market and Potential

Successful sales in EU countries, Georgia, Azerbaijan, and Vietnam serve as convincing proof of commercial viability and market demand.



**5-7%**

Growth of the biopharmaceutical market

The biopharmaceutical market in the UK and EU is estimated at billions of pounds sterling and shows an annual growth of 5-7%.

**£1.5-2M**

Projected turnover of Larifan UK

Larifan in the UK is projected to have an annual turnover in the range of £1.5 to £2 million, with growth potential up to £5 million and beyond.

**£0.5-1.5M**

Contribution of the cosmetic line

The cosmetic product line generates additional annual revenue ranging from £500,000 to £1.5 million.

# 6. Business Model and Go-to-Market Strategy

01

## MHRA Registration

MHRA registration and marketing authorization.

02

## Sales Channels

Sales through NHS, private clinics and pharmacies; cosmetic distribution – retail and online.

03


## Marketing

Focus on medical marketing and educational campaigns.

04

## Development of new products

IV solution product



# 7. Company Roles



## Orioled HUB

RA, legal support, liaison with regulators.

[Home](#)



## Larifan

Manufacturer of biopharmaceuticals and owner (MAH) of injections and cosmetics.

[Larifan - For Protection Every Day](#)



## AS KEVELT (Estonia)

Official CDMO partner, certified manufacturer of injectable Larifan forms according to EUGMP standards.

[Home - AS Kevelt](#)



## Advance Medicinal Consulting Ltd

Company for marketing, sales, and business development in UK market.

# 8. Financial Plan and Investments

## Required Investments

# £500,000

for registration, marketing, and production expansion

📄 **Investor Proposal:** We are offering 10% equity in Advance Medicinal Consulting Ltd for this investment amount. Additionally, we propose a buyback option after two years with 24% annual interest rate.

## Main expense categories:

- Registration
- Marketing
- Logistics
- Product promotion

## Projected Revenue



**Return on investment:** 1.5-2 years

Initial £1.5–2 million, growing to £5 million and more.

# 9. Risks and Management

<b>Risk Type</b>	<b>Management Strategy</b>
Regulatory Risks	Professional RA Orioled HUB Product already registered in Europe (ATC code LO3AX immunostimulant)
Market Risks	Product line diversification, effective marketing
Manufacturing Risks	GMP compliance, partner quality control
Financial Risks	Phased financing and expense control

# 10. Team



## Larifan

Dr.Guna Feldmane

*medical scientist and researcher*

Leading biotechnologists and medical experts.



## Orioled HUB

Aleksandr Dzalagonija

*CEO/ OWNER*

Registration and regulatory specialists.



## Advance Medicinal Consulting LTD

Kristaps Kolovs

*Project developer*

Professional marketing and sales team.



## CDMO Partner KEVELT AS

Proven manufacturer with international certifications.

Conclusion

# 11. Conclusion



## Innovative Product

Larifan is an innovative, proven product with high potential in the UK and European markets.



## Partner Synergy

The synergy of Orioled HUB, Larifan, KEVELT AS, and Advance Medicinal Consulting ensures effective market entry and sustainable development.



## Investor Invitation

We invite investors to collaborate on financing the registration and marketing launch.

# Invest in the Future of Biotechnology

[info@orioled.eu](mailto:info@orioled.eu)

